The Alsace BioValley biotech and health cluster and BIOPRO Baden-Württemberg signed a memorandum of understanding on 9th January 2014 whose objective is to further expand the excellent cooperation between the two regions.
Baden-Württemberg and Alsace are strong regions in the field of pharmaceutical biotechnology and medical technology, both in terms of scientific excellence and economic power. Alongside Switzerland, the two regions in the heart of Europe are among the world's economic powerhouses. Both regions can benefit from one another’s strengths by fostering innovation through cooperation between companies and research institutions in the life sciences sector.
Under the agreement, BIOPRO Baden-Württemberg and Alsace BioValley will support companies and research institutions in their search for suitable partners and in creating impulses by organising joint events and initiating projects that are eligible for EU funding. “The successful long-standing cooperation between the two organisations in the EU-funded trinational BioValley cluster has laid an excellent foundation and brought together numerous partners from research and industry from both sides of the Rhine. “We would like to build on this in the future as well as exploiting the synergies between the two regions to a greater and better extent than before,” said Dr. Ralf Kindervater, CEO of BIOPRO Baden-Württemberg, at the signing of the bilateral agreement.
Didier Frommweiler, managing director of Alsace BioValley, adds: “Our regions also plan to work more closely together in drug research and development. The French-German Advanced Translational drug discovery Center (FGATC), which is currently being established, is a public-private partnership that brings together the University of Strasbourg, the French Institute of Health and Medical Research (INSERM), the Helmholtz Association, the University Hospital of Heidelberg, the DKFZ and Sanofi. It is open to further industrial partners from Baden-Württemberg. This is an excellent opportunity for companies on either side of the Rhine and the Alsace BioValley and BIOPRO will actively support the project.” The project will be supported by German and French funding. There will initially be four new thematic drug discovery projects per year, later increasing to eight. Some of these projects will be German.